bronchospasmolytic agent 1

Bronchospasmolytic agent 1 is a flutropium bromide compound and acts as a bronchospasmolytic agent.

Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration.

Acetic acid, 2-[4-[(2-ethyl-3-benzofuranyl)carbonyl]phenoxy]- is a compound used for antiviral activity determinations.

Anxiolytic/nonsedative agent-1 (TCS 1205) is a potent and selective GABAA agonist. Anxiolytic/nonsedative agent-1 shows appreciable affinity for the BzR in bovine brain membranes with Kis of 14, 121, 239 nM for α1β2γ2, α2β2γ2, α5β3γ2, respectively. Anxiolytic/nonsedative agent-1 shows α2 selective efficacy in vitro and anxioselective effects in vivo.

anti-TB agent 1 is a potent and orally active anti-tuberculosis agent (MICs: < 2 nM against the Mtb strains H37Rv, rRMP and rINH).

ethyl 2-[3,5-bis(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate is a synthetic compound belonging to the curcumin family. It is involved in the regulation of immune response and inflammation through inhibition of the NF-κB signaling pathway, in the regulation of antioxidant response through activation of the Nrf2 signaling pathway, and in the regulation of cell survival and proliferation through inhibition of the Akt signaling pathway.

Anticonvulsant agent 1 is an anticonvulsant compound.

Compound 11, labeled as a weak Hepatoprotective agent-1, is a naturally occurring substance extracted from the fruits of Arctium lappa L. It demonstrates modest hepatoprotective effects when applied at a concentration of 10 μM [1].

Therapeutic Agent-1, a heteroaryl compound, serves as an enzyme replacement therapy to enhance glucocerebrosidase activity in the treatment of Gaucher disease [1].

Herbicidal agent 1 ((S)-6q) exhibits superior activity compared to its racemic form [1].

Ros-generating agent 1 has anticancer activity and generates ROS by covalently modifying Sec-498 residues of TrxR. ROS-generating agent 1 reduces intracellular TrxR protein levels and promotes ROs-dependent apoptosis and ferroptosis in NCI-H460 cells.

Compound 3, a molluscicidal agent, is a saponin extractable from S. vesicaria [1].

Insecticidal agent 1 exhibits greater insecticidal potency than both obacunone and toosendanin.

Antimalarial agent 1 is an effective antimalarial agent.

Anti-MI/R injury agent 1 (compound 18), derived from Panaxatriol, represents an orally administered, potent agent against myocardial ischemia/reperfusion (MI/R) injury. It improves cell viability in cardiomyocytes subjected to oxygen-glucose deprivation and reperfusion (OGD/R)-induced injury. Furthermore, this compound significantly reduces myocardial infarction size, diminishes levels of circulating cardiac troponin I (cTnI), and mitigates cardiac tissue damage in rat models [1].

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

Compound 3l, a paclitaxel derivative known as Microtubule Stabilizing Agent-1, effectively enhances tubulin polymerization and demonstrates antitumor efficacy [1].

Anti-Trypanosoma cruzi agent-1 (Compd E5) has a potent anti-Toxoplasma effect.

Anti-neurodegeneration agent 1 a neurodegeneration-targeting agent.

Antileishmanial agent-1 demonstrates activity against both L. amazonensis promastigotes (IC 50 = 15.52 μM) and intracellular amastigotes (IC 50 = 4.10 μM).

Anti-MRSA agent 1 is an MRSA inhibitor with an MIC value of 0.5 μg/mL and is effective in alleviating the effects of MRSA resistance.

Anti-melanoma agent 1 (Compound 5m) is an anti-melanoma agent that induces apoptosis.

Analgesic agent-1 is a potent analgesic that exhibits significant analgesic activity.

Anti-TSWV agent 1 is a highly effective inactivator (EC50:144 μg/mL) of tomato spotted wilt virus (TSWV).

Anti-osteoporosis agent-1 (comp 4aa) is an effective RPA (replication protein A) inhibitor, demonstrating potency with an IC50 value of 18 μM [1].

Lipid-lowering agent-1 is a potent lipid-lowering agent that significantly inhibits the pharmacological effects of low-density lipoprotein cholesterol (LDLC) and promotes the production of high-density lipoprotein cholesterol (HDLC).Lipid-lowering agent-1 significantly reduces fat in rats on a high-fat diet.

Anti-NASH Agent 1 (Compound 3d), derived from Elafibranor, serves as a strong PPAR-α/δ agonist aimed at treating nonalcoholic steatohepatitis (NASH). At dosages of 3-10 mg/kg over four weeks, this compound ameliorates hyperlipidemia, liver fat degeneration, and inflammation in a methionine-choline deficiency (MCD)-induced NASH mouse model, exhibiting minimal hepatotoxicity while providing substantial hepatic protection [1].

Anti-Heart Failure Agent 1 is an orally available compound suitable for the treatment of heart failure without inducing vomiting, nausea, and restlessness.

Anti-inflammatory agent 1 is an anti-inflammatory compound.

Anti-hyperglycemic agent 1 is a potent inhibitor of alpha-glucosidase (IC50: 0.53 μM). anti-Hyperglycemic agent 1 can be used to study diabetes.

Antiplatelet agent 1 is a ticagrelor analogue that exhibits anti-platelet effects and can be used in platelet agglutination studies.

Anti gram-positive/negative bacteria agent 1 is an antibiotic linked with a synthetic MECAM-based siderophore, serving as a conjugate aimed at combating gram-positive and gram-negative bacteria.

Anabolic agent-1 is a novel bone morphogenetic protein-2 up regulator, with the capability of rectifying bone loss in patients and exhibiting versatile clinical applicability.

Hypoglycemic agent 1 has an action for lowering blood sugar. It acts as a therapeutic and/or prophylactic agent for diabetes.

Anti-infective agent 1 (compound 3a) serves as a potent, selective antiprotozoal and antimycobacterial compound. It showcases antiparasitic efficacy against P. falciparum and T. brucei rhodesiense, demonstrating IC50 values of 10.95 and 0.06 μM, respectively. Moreover, it displays antimycobacterial properties against Mycobacterium smegmatis, exhibiting a minimum inhibitory concentration (MIC) of 8 μg/mL [1].

Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy. It is primarily utilized in the study of coronavirus and Ebola virus (EBOV).

GABAA receptor agent 1 has strong anticonvulsant activity and is a high affinity ligand of GABAA receptor.

Antituberculosis Agent-1 (Compound 8a) is an effective antituberculosis agent, demonstrating a minimum inhibitory concentration (MIC) of 3.84 μg/mL against Mycobacterium tuberculosis H37Rv [1].

Apoptotic agent-1 (Compound 8a) induces Fas receptor and Cyto C genes over-expression that is an apoptotic agent with high antiproliferative activity against cancer cells as well as low cytotoxic effect [1].

Antitubulin Agents-1, an antitubulin agent, disrupts microtubules (Microtubule/Tubulin) and enhances α-tubulin acetylation, exhibiting anticancer effects.

Antiarrhythmic agent-1 (example I), functioning as an antiarrhythmic agent and an IKr potassium channel blocker (IC 50 <1 μM), effectively inhibits cardiac arrhythmias.

Anti-IAV Agent 1-1a is an orally administered compound effective against the Influenza A virus (IAV), demonstrating inhibitory concentration 50 (IC50) values of 0.03 μM and 0.06 μM for the H1N1 strain and the Oseltamivir-resistant H1N1 strain of IAV, respectively.

Phototherapeutic agent-1, a multi-modal diagnostic agent with aggregation-induced emission properties, possesses the capacity to generate reactive oxygen species (ROS) under illumination. This capacity enables Phototherapeutic agent-1 to effectively eliminate cancer cells and tumor tissue [1].

Antistaphylococcal agent 1 is an antistaphylococcal therapeutic agent.

Antitrypanosomal agent 1 is a potent and selective trypanothione reductase (TR) inhibitor (IC50: 3.3 μM). Antitrypanosomal agent 1 inhibits glutathione reductase (IC50: 64.8 μM) and T. brucei (EC50: 1 μM).

Antimycobacterial agent-1 (compound 33) demonstrates potent antimycobacterial activity against Mycobacterium tuberculosis H37Ra, with a minimal inhibitory concentration (MIC) value of 1 μg/ml. Notably, antimycobacterial agent-1 exhibits low cytotoxicity in normal cells, as evidenced by an IC50 value of 143.2 μg/ml in Vero cells [1].

Anticandidal agent-1 (compound c2) is a potent and broad-spectrum anticandidal agent that inhibits biofilm through blocking hyphal elongation and filamentation. Anticandidal agent-1 exhibits anticandidal activity against C. glabrata and C. albicans, with MIC 50 values of 13.51 and 8.65 μg/mL, respectively [1].

Antimicrobial Agent-1 (compound 6C) shows strong activity (MIC = 2 μg/mL) against TolC mutant E. coli. Additionally, it synergistically interacts with Colistin to exhibit enhanced activity against Gram-negative bacteria. Importantly, Antimicrobial Agent-1 exhibits no cytotoxic effects on mammalian cell lines. Its MIC values on Caco-2 and Vero cell lines are greater than 128 μg/mL [1].

anti-TNBC agent-1 is a highly effective compound specifically designed to target and combat triple-negative breast cancer (TNBC). It demonstrates remarkable potency against various breast cancer cell types, with IC50 values spanning from 0.20 μM to 0.27 μM. The mechanism of action of anti-TNBC agent-1 involves inducing apoptosis in SUM-159 cells through the mitochondria pathway, as well as causing G1 phase arrest in these cells.